Jazz Pharmaceuticals plc Stock
Price
Target price
€153.90
€153.90
-1.310%
-2.05
-1.310%
€173.58
08:00 / Tradegate
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Jazz Pharmaceuticals plc Stock
We can see a decrease in the price for Jazz Pharmaceuticals plc. Compared to yesterday it has lost -€2.050 (-1.310%).
With 42 Buy predictions and not a single Sell prediction Jazz Pharmaceuticals plc is an absolute favorite of our community.
With a target price of 173 € there is a slightly positive potential of 12.41% for Jazz Pharmaceuticals plc compared to the current price of 153.9 €.
Pros and Cons of Jazz Pharmaceuticals plc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Jazz Pharmaceuticals plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | -1.310% | 31.603% | 33.748% | 40.495% | 33.748% | 9.377% | 27.828% |
| Repligen Corp. | 1.870% | 4.881% | 1.032% | 13.336% | -5.573% | -22.465% | -15.478% |
| Opko Health Inc. | -0.760% | -3.929% | -15.882% | -30.863% | -24.651% | -32.180% | -68.495% |
| Amicus Therapeutics Inc. | -1.230% | 3.896% | 16.788% | -11.602% | -12.568% | -23.047% | -57.672% |
Comments
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
